IL-9 Producing Tumor-Infiltrating Lymphocytes and Treg Subsets Drive Immune Escape of Tumor Cells in Non-Small Cell Lung Cancer.
IL-9
NSCLC
TIL
immune escape
tumor immunotherapy
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
01
2022
accepted:
10
03
2022
entrez:
6
5
2022
pubmed:
7
5
2022
medline:
10
5
2022
Statut:
epublish
Résumé
Although lung cancer is the leading cause of cancer deaths worldwide, the mechanisms how lung cancer cells evade the immune system remain incompletely understood. Here, we discovered IL-9-dependent signaling mechanisms that drive immune evasion in non-small cell lung cancer (NSCLC). We found increased IL-9 and IL-21 production by T cells in the tumoral region of the lung of patients with NSCLC, suggesting the presence of Th9 cells in the lung tumor microenvironment. Moreover, we noted IL-9 producing Tregs in NSCLC. IL-9 target cells in NSCLC consisted of IL-9R+ tumor cells and tumor-infiltrating lymphocytes. In two murine experimental models of NSCLC, and
Identifiants
pubmed: 35514957
doi: 10.3389/fimmu.2022.859738
pmc: PMC9065342
doi:
Substances chimiques
Interleukin-9
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
859738Subventions
Organisme : NIAID NIH HHS
ID : R01 AI057459
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI060519
Pays : United States
Informations de copyright
Copyright © 2022 Heim, Yang, Tausche, Hohenberger, Chiriac, Koelle, Geppert, Kachler, Miksch, Graser, Friedrich, Kharwadkar, Rieker, Trufa, Sirbu, Neurath, Kaplan and Finotto.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Nat Commun. 2018 Nov 9;9(1):4736
pubmed: 30413714
Nat Immunol. 2008 Nov;9(11):1297-306
pubmed: 18849990
Br J Cancer. 2019 Apr;120(9):903-912
pubmed: 30956278
Lancet Diabetes Endocrinol. 2013 Dec;1(4):295-305
pubmed: 24622415
Oncoimmunology. 2012 Aug 1;1(5):642-648
pubmed: 22934256
Nat Immunol. 2010 Jun;11(6):527-34
pubmed: 20431622
Nat Rev Immunol. 2015 May;15(5):295-307
pubmed: 25848755
Eur J Cancer. 2009 Sep;45 Suppl 1:375-6
pubmed: 19775636
Br J Cancer. 2015 Sep 15;113(6):902-13
pubmed: 26348446
Immunity. 2009 May;30(5):646-55
pubmed: 19464987
Nat Commun. 2011 Dec 20;2:600
pubmed: 22186896
J Immunol. 2004 May 15;172(10):6101-6
pubmed: 15128795
Nat Commun. 2015 Sep 14;6:8266
pubmed: 26365427
Onco Targets Ther. 2018 Dec 03;11:8623-8632
pubmed: 30584321
Mol Cell Biol. 2004 Sep;24(18):8037-47
pubmed: 15340066
Nat Immunol. 2008 Dec;9(12):1341-6
pubmed: 18931678
J Allergy Clin Immunol. 2000 Jan;105(1 Pt 1):108-15
pubmed: 10629460
Semin Immunopathol. 2017 Jan;39(1):39-46
pubmed: 27832300
Int Rev Immunol. 1998;16(3-4):345-64
pubmed: 9505195
Clin Exp Pharmacol Physiol. 2017 Feb;44(2):213-221
pubmed: 27797409
Nat Immunol. 2012 Oct;13(10):981-90
pubmed: 22842344
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12885-90
pubmed: 19433802
Immunol Rev. 2013 Mar;252(1):104-15
pubmed: 23405898
Nat Immunol. 2016 Nov;17(11):1291-1299
pubmed: 27618553
Cancer Res. 2018 Jul 1;78(13):3619-3633
pubmed: 29691251
Nat Immunol. 2008 Dec;9(12):1347-55
pubmed: 18997793
Br J Cancer. 2017 Nov 21;117(11):1644-1655
pubmed: 29016555
Cancer Res. 2000 Jul 15;60(14):3971-7
pubmed: 10919676
Nat Immunol. 2014 Aug;15(8):758-66
pubmed: 24973819
Oncoimmunology. 2016 Dec 14;6(1):e1256526
pubmed: 28197372
J Allergy Clin Immunol. 2019 Mar;143(3):937-939
pubmed: 30193841
J Nucl Med. 2021 Jul 1;62(7):926-933
pubmed: 33246978
Nat Commun. 2017 May 12;8:15366
pubmed: 28497800
Br J Cancer. 2016 Oct 25;115(9):e11
pubmed: 27657338
Am J Respir Crit Care Med. 2012 Dec 1;186(11):1168-79
pubmed: 23065014
Cytokine Growth Factor Rev. 2015 Oct;26(5):559-68
pubmed: 26182974
Nat Med. 2002 Jun;8(6):567-73
pubmed: 12042806
Nat Immunol. 2014 Jul;15(7):676-86
pubmed: 24908389
Nat Med. 2018 Jul;24(7):994-1004
pubmed: 29892065
Lung Cancer. 2019 Jan;127:153-163
pubmed: 30642544
J Immunol. 1994 Nov 1;153(9):3989-96
pubmed: 7930607
J Biol Chem. 2012 May 4;287(19):15445-57
pubmed: 22427656
Nat Med. 2012 Aug;18(8):1248-53
pubmed: 22772464
Oncoimmunology. 2018 Apr 25;7(8):e1456612
pubmed: 30221050
Cell. 2021 Dec 9;184(25):6101-6118.e13
pubmed: 34852236
J Immunol. 2016 Apr 15;196(8):3297-304
pubmed: 26976954
J Immunol. 2011 Jan 1;186(1):83-91
pubmed: 21115728
Nat Immunol. 2011 Jan;12(1):96-104
pubmed: 21151104
Br J Cancer. 2013 Jul 9;109(1):76-82
pubmed: 23807161
J Clin Invest. 2013 Nov;123(11):4641-53
pubmed: 24216482
Nat Commun. 2018 Nov 15;9(1):4803
pubmed: 30442929
Immunity. 2012 Oct 19;37(4):660-73
pubmed: 23041064
Nat Rev Immunol. 2013 Nov;13(11):777-89
pubmed: 24113868
Nat Commun. 2017 May 30;8:15628
pubmed: 28555647
J Immunol. 2011 Mar 15;186(6):3283-8
pubmed: 21368237
J Clin Invest. 2012 Nov;122(11):4160-71
pubmed: 23064366
Thorax. 2015 Feb;70(2):184
pubmed: 25535292